home / stock / allk / allk news

ALLK News and Press, Allakos Inc. From 05/07/20

Stock Information
Company Name: Allakos Inc.
Stock Symbol: ALLK
Market: NASDAQ
Website: allakos.com
Menu
ALLK ALLK Quote ALLK Short ALLK News ALLK Articles ALLK Message Board
Get ALLK Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 4 DAYS to APPLICATION DEADLINE

SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . Only four days remain until the May 11, 2020 lead plaintiff deadline in a securities fraud class action that has been...
ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 5 DAY DEADLINE ALERT

SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . Only five days remain until the May 11, 2020 lead plaintiff deadline in a securities fraud class action that has be...

ALLK - Allakos Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Allakos Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - May 5, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (NASDAQ: ALLK) ("Allakos" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities cla...

ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 7 DAY DEADLINE ALERT

SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . The May 11, 2020 lead plaintiff deadline in a securities fraud class action that has been filed against the company...
ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALLK, CRON, FNKO Investors: 7-DAY APPLICATION DEADLINE ALERT, Investors with Losses Should Contact Firm

SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases, including the upcoming May 11, 2020 lead plaintiff...

ALLK - Allakos Announces Positive Interim Results from an Open-Label Extension Study of Antolimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis

-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment -- REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasda...

ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALLK, CRON, FNKO Investors: 13-DAY DEADLINE ALERT, Investors with Losses Should Contact Firm

SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including the upcoming May 11, 2020 lead plaintiff app...
ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALGN, ALLK, CRON, VMW Investors, Encourages Investors with Losses to Contact Firm, Reminds of Critical Upcoming Deadlines

SAN FRANCISCO, April 22, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases, including upcoming application deadlines, can be ...

ALLK - Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting

REDWOOD CITY, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three post...

ALLK - U.S. IPO Weekly Recap: Keros Therapeutics Rises 35% As Biotechs Beat The IPO Shutdown

Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) finished the week up 35%, affirming that the biotech industry won't be deterred by current market volatility. Oncology biotech Keros Therapeutics priced its upsized IPO at the high end to raise $96 million at a $325 m...
Previous 10 Next 10